TY - JOUR
T1 - The prognostic significance of histologic type in early stage cervical cancer - A multi-institutional study
AU - Winer, Ira
AU - Alvarado-Cabrero, Isabel
AU - Hassan, Oudai
AU - Ahmed, Quratulain F.
AU - Alosh, Baraa
AU - Bandyopadhyay, Sudeshna
AU - Thomas, Sumi
AU - Albayrak, Samet
AU - Talukdar, Shobhana
AU - Al-Wahab, Zaid
AU - Elshaikh, Mohamed A.
AU - Munkarah, Adnan
AU - Morris, Robert
AU - Ali-Fehmi, Rouba
N1 - Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Background Cervical adenocarcinomas (ADC) have been viewed as more aggressive than squamous cell carcinoma (SCC). We analyzed an international cohort of early stage cervical cancer to determine the impact of histologic type. Methods Retrospective analysis of patients with SCC (148 patients) and ADC (130 patients) stages IA1-IB2 who underwent surgery at our three institutions (two from Detroit, one from Mexico) from 2000-2010 was performed for: age, stage, tumor size, lymphovascular invasion (LVI), invasion depth, lymph node status (LN), recurrence and survival. Pathologic review proceeded inclusion. Results In the Latino population, ADC's tended to be higher grade (p = 0.01), while SCC's were larger with deeper invasion (p < 0.001). LVI and LN were not significantly different. Recurrence rate (RR) was 8% (8/101) in ADC and 11.8% (9/76) in SCCs. 5 year survival (OS) was equivalent (98.2% and 95.2% for ADC and SCC respectively, p = 0.369). In the Detroit cohort, we noted no difference in size, grade, depth of invasion, LVI, LN. RR was 8/72 (13.7%) for SCC and 4/29 (13.7%) but not statistically different between the tumor types (p = 0.5). 5 year survival was 91% and 92% for ADC and SCC, respectively. In this population 33% of the patients with SCC and 34% of the patients with ADC received adjuvant chemo-radiation (p = 0.4). Histologic type demonstrated no significant outcome difference for any type of adjuvant therapy. Conclusion Comparing early stage disease cervical ADC and SCC suggests equivalent recurrence and survival. Therefore, the paradigm of more aggressive management of early stage cervical ADC warrants further investigation.
AB - Background Cervical adenocarcinomas (ADC) have been viewed as more aggressive than squamous cell carcinoma (SCC). We analyzed an international cohort of early stage cervical cancer to determine the impact of histologic type. Methods Retrospective analysis of patients with SCC (148 patients) and ADC (130 patients) stages IA1-IB2 who underwent surgery at our three institutions (two from Detroit, one from Mexico) from 2000-2010 was performed for: age, stage, tumor size, lymphovascular invasion (LVI), invasion depth, lymph node status (LN), recurrence and survival. Pathologic review proceeded inclusion. Results In the Latino population, ADC's tended to be higher grade (p = 0.01), while SCC's were larger with deeper invasion (p < 0.001). LVI and LN were not significantly different. Recurrence rate (RR) was 8% (8/101) in ADC and 11.8% (9/76) in SCCs. 5 year survival (OS) was equivalent (98.2% and 95.2% for ADC and SCC respectively, p = 0.369). In the Detroit cohort, we noted no difference in size, grade, depth of invasion, LVI, LN. RR was 8/72 (13.7%) for SCC and 4/29 (13.7%) but not statistically different between the tumor types (p = 0.5). 5 year survival was 91% and 92% for ADC and SCC, respectively. In this population 33% of the patients with SCC and 34% of the patients with ADC received adjuvant chemo-radiation (p = 0.4). Histologic type demonstrated no significant outcome difference for any type of adjuvant therapy. Conclusion Comparing early stage disease cervical ADC and SCC suggests equivalent recurrence and survival. Therefore, the paradigm of more aggressive management of early stage cervical ADC warrants further investigation.
KW - Adenocarcinoma (ADC)
KW - Squamous cell carcinoma (SCC)
UR - http://www.scopus.com/inward/record.url?scp=84930044105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930044105&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2015.02.005
DO - 10.1016/j.ygyno.2015.02.005
M3 - Article
C2 - 25677061
AN - SCOPUS:84930044105
SN - 0090-8258
VL - 137
SP - 474
EP - 478
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 3
ER -